These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31291214)

  • 1. Lurasidone Malabsorption Following Bariatric Surgery: A Case Report.
    Ward HB; Yudkoff BL; Fromson JA
    J Psychiatr Pract; 2019 Jul; 25(4):313-317. PubMed ID: 31291214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?
    Keks NA; Hope J; Castle D
    Australas Psychiatry; 2016 Jun; 24(3):289-91. PubMed ID: 27036122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
    Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
    Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
    Chapel S; Chiu YY; Hsu J; Cucchiaro J; Loebel A
    Clin Ther; 2016 Jan; 38(1):4-15. PubMed ID: 26730454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.
    Findling RL; Goldman R; Chiu YY; Silva R; Jin F; Pikalov A; Loebel A
    Clin Ther; 2015 Dec; 37(12):2788-97. PubMed ID: 26631428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.
    Greenblatt DJ; Harmatz JS; Ryan MJ; Chow CR
    J Clin Psychopharmacol; 2018 Aug; 38(4):289-295. PubMed ID: 29851709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.
    Greenberg WM; Citrome L
    Clin Pharmacokinet; 2017 May; 56(5):493-503. PubMed ID: 27722855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurasidone in Children and Adolescents: Systematic Review and Case Report.
    Channing J; Mitchell M; Cortese S
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):428-436. PubMed ID: 30004236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of lurasidone for bipolar depression.
    Loebel A; Xu J; Hsu J; Cucchiaro J; Pikalov A
    Ann N Y Acad Sci; 2015 Nov; 1358():95-104. PubMed ID: 26771990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current State of Bariatric Surgery: Procedures, Data, and Patient Management.
    Rogers AM
    Tech Vasc Interv Radiol; 2020 Mar; 23(1):100654. PubMed ID: 32192634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Lurasidone-Induced Polydipsia Complicated by Hyponatremia in a Patient With Bipolar Disorder.
    Li ST; Yeh YW
    Clin Neuropharmacol; 2021 Nov-Dec 01; 44(6):243-244. PubMed ID: 34561339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating lurasidone as a treatment option for bipolar disorder.
    Ali Z; Tegin C; El-Mallakh RS
    Expert Opin Pharmacother; 2020 Feb; 21(3):253-260. PubMed ID: 31957501
    [No Abstract]   [Full Text] [Related]  

  • 14. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
    Macaluso M; Kazanchi H; Preskorn SH
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression.
    Modugula H; Kumar A
    CNS Neurol Disord Drug Targets; 2020; 19(2):109-114. PubMed ID: 32124704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
    Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
    Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research.
    Kouidrat Y; Amad A; Stubbs B; Moore S; Gaughran F
    Obes Surg; 2017 Jul; 27(7):1889-1895. PubMed ID: 28508277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malabsorption after bariatric surgery can increase the risk of post-operative complications of the following plastic surgery].
    Hasanbegovic E; Sørensen JA
    Ugeskr Laeger; 2014 Jun; 176(25):. PubMed ID: 25352280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
    Naccarato M; Hall E; Wai A; Ostrowski M; Carvalhal A
    Antivir Ther; 2016; 21(8):735-738. PubMed ID: 27328703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perinatal use of lurasidone for the treatment of bipolar disorder.
    Montiel C; Newmark RL; Clark CT
    Exp Clin Psychopharmacol; 2022 Apr; 30(2):249-252. PubMed ID: 34291994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.